Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Journal of Obstrectic Anaesthesia and Critical Care
Search articles
Home Print this page Email this page Small font size Default font size Increase font size Users Online: 319

 Table of Contents  
LETTERS TO EDITOR
Year : 2020  |  Volume : 10  |  Issue : 2  |  Page : 150-151

Is intramyometrial carboprost troublesome?


Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Date of Submission16-Jan-2020
Date of Acceptance14-Mar-2020
Date of Web Publication20-Aug-2020

Correspondence Address:
Dr. Shalvi Mahajan
Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joacc.JOACC_5_20

Rights and Permissions

How to cite this article:
Garg S, Kumar S, Mahajan S. Is intramyometrial carboprost troublesome?. J Obstet Anaesth Crit Care 2020;10:150-1

How to cite this URL:
Garg S, Kumar S, Mahajan S. Is intramyometrial carboprost troublesome?. J Obstet Anaesth Crit Care [serial online] 2020 [cited 2020 Oct 21];10:150-1. Available from: https://www.joacc.com/text.asp?2020/10/2/150/292744



Postpartum hemorrhage (PPH) is a common complication and major cause of maternal mortality after delivery. We hereby report a case of a young healthy primigravida female who developed a life-threatening cardiovascular change following intramyometrial injection of carboprost for atonic uterus during cesarean section.

A 24 years old primigravida, 37 weeks of gestation with breech, was planned for elective lower segment cesarean section. Pre-Anesthesia checkup was unremarkable. With standard ASA monitoring, the subarachnoid block was given in sitting position, using a midline approach with 8 mg of 0.5% bupivacaine (hyperbaric) and 25 mcg fentanyl (total volume 2.3 mL) and anesthesia level was achieved up to the T6 dermatome. Oxytocin 25 IU IV infusion was started at 5 IU.h − 1 as per institutional protocol after the delivery of the baby. The uterine contraction was inadequate after the initial measures and intramyometrial carboprost 250 mcg (Carboprost Tromethamine, 250 mcg, Neon Laboratories Limited) was administered after negative aspiration for blood. After 1–2 min, the patient complained uneasiness and headache. She developed tachycardia (heart rate-140/min), ST-segment depression in 5-lead ECG, and blood pressure (BP) increased to 210/120 mmHg without a drop in oxygen saturation [Figure 1]. She was managed symptomatically with IV esmolol 20 mg and labetalol 10 mg. After 4–5 min, the heart rate decreased to 90/min and BP to 105/61 mmHg. ST-segment depression resolved gradually. Arterial blood gas was performed during this event, showed pH 7.37, pO2 436.7 mmHg, pCO2 30.4 mmHg, Hco3-17.4, BE-6.8, Na 138.4 mEq/L, K 3.5 mEq/L with blood sugar (RBS) 71 mg/dL. Dextrose 5% 100 mL was given and repeat measurement of RBS was 128 mg/dL. Despite this event, the adequate uterine contraction was achieved and the rest of the surgery was uneventful. The patient was comfortable and kept in the postanesthesia recovery unit for monitoring. 12-lead ECG was done postoperatively which showed no ST-T changes. The rest of the hospital course was uneventful.
Figure 1: Hemodynamics and ST-segment changes following intramyometrial carboprost administration

Click here to view


Carboprost is a synthetic prostaglandin F2 alpha and is FDA approved for second-line oxytocic agent following oxytocin and ergometrine. It can be administered intramuscular or intramyometrial or intravascular to control PPH. Intramyometrial injection is preferred over the intramuscular because of its early onset of action (5 min vs 15 min) by causing direct contraction of uterine smooth muscles. Intravascular use of carboprost has a very limited role due to its multiple side effects like nausea, vomiting, diarrhea, bronchospasm, and hypertension.[1]

Our patient developed hypertension with significant ST wave changes which resolved after symptomatic treatment. It may be due to accidental intravascular administration of carboprost during intramyometrial injection due to increased vascularity of uterus despite negative aspiration for blood. PF2-alpha exerts its action through G-protein coupled F Prostanoid receptors (FP), present in the medial layer of resistance vessels and cardiac myocytes which lead to hypertension and tachycardia.[2]

However, there is limited literature related to cardiac complications following its intramuscular (intramyometrial use). We found one similar case report by Mahey, observed increase in heart rate (175/min) and blood pressure (220/135 torr) without a change in oxygen saturation and carbon dioxide levels with intramyometrial injection of dinoprost for management of PPH.[3] Both dinoprost and carboprost are PG F2 alpha agonists. In another case report, Cares et al. mentioned the sudden collapse and death of two healthy young females following intra-amniotic use of PGF2alpha as an abortifacient.[4] Sachet et al. studied the systemic effects of IV infusion of PGF2α in pregnant patients and observed a 40% increase in cardiac output, 25% increase in femoral arterial pressure, 125% increase in pulmonary artery pressure with no significant change in the heart rate.[5]

To conclude, both obstetricians and anesthesiologists should be more vigilant while injecting intramyometrial carboprost for hemodynamic changes resulting in life-threatening complications.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Granstrom L, Ekman G, Ulmsten U. Intravenous infusion of 15 methyl prostaglandin F2α in women with heavy postpartum haemorrhage. Acta Obstet Gynecol Scand 1989;68:365-7.  Back to cited text no. 1
    
2.
Zhang J, Gong Y, Yu Y. PG F2α receptor: A promising therapeutic target for disease. Front Pharmacol 2010;1:1-7.  Back to cited text no. 2
    
3.
Mayhew JF. Hypertensive response to dinoprost under anesthesia. Anesth Analges 1986;65:1248.  Back to cited text no. 3
    
4.
Cares W, Jordan HV. Sudden collapse and death of women obtaining abortions induced with prostaglandin F2 alpha. Am I Obstet Gynecol 1979;133:398-400.  Back to cited text no. 4
    
5.
Secher NJ, Thayssen P, Arnsbo P, Olsen J. Effect of prostaglandin E and F on the systemic and pulmonary circulation in pregnant anesthetized women. Acta Obstet Gynecol Scand 1982;61:213-8.  Back to cited text no. 5
    


    Figures

  [Figure 1]



 

Top
 
 
Search
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)  

 
  In this article
References
Article Figures

 Article Access Statistics
    Viewed85    
    Printed4    
    Emailed0    
    PDF Downloaded36    
    Comments [Add]    

Recommend this journal